Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adherium Ltd. ( (AU:ADR) ) has shared an announcement.
Adherium Limited has applied to the ASX for quotation of 1,683,193,914 new fully paid ordinary shares, to be issued on 24 February 2026 under its ticker ADR. The substantial share issuance, previously flagged to the market, will significantly expand the company’s quoted capital base and may influence its funding capacity, market liquidity, and ownership structure for existing and new investors.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australia-listed healthcare technology company focused on respiratory disease management. It develops and supplies connected respiratory devices and digital health solutions designed to support patients, clinicians, and payers in monitoring inhaler use and improving treatment adherence in chronic respiratory conditions.
Technical Sentiment Signal: Sell
Current Market Cap: A$21.64M
See more data about ADR stock on TipRanks’ Stock Analysis page.